High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia
July 17, 2017
| By Susan Keown / Fred Hutch News Service
Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.
New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
30 years after an early BMT, a cancer survivor pays it forward by helping researchers ‘make it better for others’
March 29, 2017
| By Diane Mapes / Fred Hutch News Service
The road to a cure was not easy for Mike Rubin, who underwent a bone marrow transplant in 1987. But 30 years after the lifesaving procedure, this survivor and Fred Hutch fundraiser is celebrating -- and paying it forward so others can do the same.
Dr. Keith Jerome, collaborators awarded amfAR grant for HIV cure research; NCI selects Hutch survivorship study among top 10 research highlights in 2016; and Dr. Nancy Davidson receives 2017 Women in Oncology Award